GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Novo Integrated Sciences Inc (OTCPK:NVOS) » Definitions » Cash Flow from Financing

NVOS (Novo Integrated Sciences) Cash Flow from Financing : $5.59 Mil (TTM As of May. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Novo Integrated Sciences Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in May. 2024, Novo Integrated Sciences paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $2.02 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It spent $0.20 Mil on other financial activities. In all, Novo Integrated Sciences earned $1.82 Mil on financial activities for the three months ended in May. 2024.


Novo Integrated Sciences Cash Flow from Financing Historical Data

The historical data trend for Novo Integrated Sciences's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Integrated Sciences Cash Flow from Financing Chart

Novo Integrated Sciences Annual Data
Trend Dec14 Dec15 Dec16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.07 -0.27 4.32 -0.43 0.76

Novo Integrated Sciences Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 0.47 3.30 - 1.82

Novo Integrated Sciences Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Novo Integrated Sciences's Cash from Financing for the fiscal year that ended in Aug. 2023 is calculated as:

Novo Integrated Sciences's Cash from Financing for the quarter that ended in May. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in May. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novo Integrated Sciences  (OTCPK:NVOS) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Novo Integrated Sciences's issuance of stock for the three months ended in May. 2024 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Novo Integrated Sciences's repurchase of stock for the three months ended in May. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Novo Integrated Sciences's net issuance of debt for the three months ended in May. 2024 was $2.02 Mil. Novo Integrated Sciences received $2.02 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Novo Integrated Sciences's net issuance of preferred for the three months ended in May. 2024 was $0.00 Mil. Novo Integrated Sciences paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Novo Integrated Sciences's cash flow for dividends for the three months ended in May. 2024 was $0.00 Mil. Novo Integrated Sciences received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Novo Integrated Sciences's other financing for the three months ended in May. 2024 was $-0.20 Mil. Novo Integrated Sciences spent $0.20 Mil on other financial activities.


Novo Integrated Sciences Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Novo Integrated Sciences's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Integrated Sciences Business Description

Traded in Other Exchanges
N/A
Address
11120 NE 2nd Street, Suite 100, Bellevue, WA, USA, 98004
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.
Executives
Sarfaraz Ali director C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Robert Letterio Oliva director 115 BELFIELD RD, TORONTO A6 L0J 1C0
Sterling M. Jimenez officer: Principal Financial Officer C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Michael Ross Pope director 1045 PROGRESS CIRCLE, LAWRENCEVILLE, GEORGIA GA 30043
Alex Flesias director 41 LANDMARK COURT, UNIONVILLE A6 L3R 9N7
Michael Joseph Gaynor director 49 BALMORAL ST, KEMPTVILLE A6 K0G 1J0
Robert Mattacchione director, 10 percent owner, officer: Chief Executive Officer 79 SELVAPIANO CRES, WOODBRIDGE A6 L4H 0X1
Pierre Joseph Dalcourt director, 10 percent owner 35 BRYANT ST , BOX 2230, HEARST A6 P0L 1N0
Christopher Mehlin David director, officer: President 10425 SE 22ND ST., BELLEVUE WA 98004
Thomas Edward Bray officer: Principal Financial Officer C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Rebecca Aw Mcdonald officer: Chief Accounting Officer 1301 INTERNATIONAL SPEEDWAY BLVD., DELAND FL 32724
James Jr Teters director 1200 FLIGHTLINE BLVD, STE 5, DELAN FL 32724
Phyllis Rouse officer: secretary 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Jay Hilden officer: President & CEO 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Robert Adamo director 1200 FLIGHTLINE BOULEVARD, SUITE 5, DELAND FL 32724